The Clinical Factors Related to the Efficacy of Ozoralizumab in Patients with Rheumatoid Arthritis
Background/Objectives: Ozoralizumab, a tumor necrosis factor (TNF) blocker, was launched in Japan in 2022. However, there is no evidence to determine whether this biological agent is the best choice for patients with rheumatoid arthritis (RA). To investigate the clinical factors related to the efficacy of ozoralizumab,...